Notice NOT-DA-20-060 from the NIH Guide for Grants and Contracts

£300 - £400 per day: Hyper Recruitment Solutions (HRS): We are currently looking for a Computational Genetics Scientist to join the Drug Discovery function of a leading pharmaceutical company based in the Berkshire area.... Berkshire

Notice NOT-OD-20-117 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-21-024 from the NIH Guide for Grants and Contracts. This FOA supports applications for Claude D. Pepper Older Americans Independence Centers (OAICs), centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. The OAIC awards are designed to develop or strengthen awardee institutions programs that focus and sustain progress on a key area in aging research related to the mission of the OAIC program.

Funding Opportunity PAR-20-228 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support collaborative pilot research projects focused on potential effects relevant to human health of chemically complex natural products and/or the causal, molecular mechanisms underlying such effects. A critical element of each proposed project must be collaboration with one or more of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (CARBON). More specifically, letters of support describing collaboration with one or more of the U19 Botanical Dietary Supplements Research Centers awarded in 2020 must be included at the time of submission. Each proposed pilot project must, with agreement of its collaborating Center(s), leverage products used in those Centers to extend understanding of their biological effects, or of their causal, molecular mechanisms of action, or increase understanding of other chemically complex natural products through use of methods developed and used in the Centers. Research approaches may range from bench through in vitro and non-human animal models to, where feasible and appropriate, obtaining additional feasibility or outcome information from clinical trials being performed by the CARBON awardees, either through inclusion of additional measures or through secondary analysis of data or specimens.

Notice NOT-AI-20-044 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-034 from the NIH Guide for Grants and Contracts

A competitive remuneration package will be offered to the successful candidate.: DHR International: The Chief Scientific Officer will build all scientific strategies and work closely with stakeholders in developing clinical and ethical protocols. Hong Kong

A competitive remuneration package will be offered to the successful candidate. : DHR International: The CEO will lead the newly set up Hong Kong Genome Institute to ensure efficient implementation of the Hong Kong Genome Project. Hong Kong

PhD in engineering, computational biology/bioinformatics, computer science, biostatistics, or related quantitative field.
From bluebird bio - Fri, 05 Jun 2020 22:13:54 GMT - View all Seattle, WA jobs

F. Hoffmann-La Roche AG: At Roche, 94,000 people across 100 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading Switzerland (CH)

Notice NOT-DE-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-DC-20-010 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-036 from the NIH Guide for Grants and Contracts

Notice NOT-AA-20-014 from the NIH Guide for Grants and Contracts

Notice NOT-AA-20-015 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-20-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies . The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U54 Centers will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Research Projects (U01), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC) and a Serological Sciences Network Coordinating Center (SSNCC) which will be managed through Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents. This FOA solicits multi-component U54 Center applications, whereas the companion FOA, RFA-CA-20-039, solicits applications for discrete U01 research projects. Successful applicants from both FOAs will become members of the Serological Sciences Network.

Funding Opportunity RFA-CA-20-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies. The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; and determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U01 Research Projects will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Centers of Excellence (U54), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC), and a Serological Sciences Network Coordinating Center (SSNCC), which will be managed through the Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents. This FOA solicits U01 research project applications, whereas the companion FOA, RFA-CA-20-038, solicits multi-component U54 Centers applications. Successful applicants from both FOAs will become members of the Serological Sciences Network.

€ 32,000. The definite salary agreement will be made during the personal interview: CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Winter laboratory at CeMM, the Research Center for Molecular Medicine of the Austrian Academy .... Vienna, Austria

Notice NOT-OD-20-111 from the NIH Guide for Grants and Contracts